Generation of a novel monoclonal antibody against inflammatory biomarker S100A8 using hybridoma technology
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jong-Pyo | - |
dc.contributor.author | Yun, Hanool | - |
dc.contributor.author | Kim, Eun-Jung | - |
dc.contributor.author | Kim, Yun-Gon | - |
dc.contributor.author | Lee, Chang-Soo | - |
dc.contributor.author | Ko, Byoung Joon | - |
dc.contributor.author | Kim, Byung-Gee | - |
dc.contributor.author | Jeong, Hee-Jin | - |
dc.date.accessioned | 2023-04-10T07:40:35Z | - |
dc.date.available | 2023-04-10T07:40:35Z | - |
dc.date.issued | 2023-06-01 | - |
dc.identifier.issn | 0141-5492 | - |
dc.identifier.issn | 1573-6776 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hongik/handle/2020.sw.hongik/31069 | - |
dc.description.abstract | Objectives: S100A8 is highly expressed in several inflammatory and oncological conditions. To address the current lack of a reliable and sensitive detection method for S100A8, we generated a monoclonal antibody with a high binding affinity to human S100A8 to enable early disease diagnosis. Results: A soluble recombinant S100A8 protein with a high yield and purity was produced using Escherichia coli. Next, mice were immunized with recombinant S100A8 to obtain anti-human S100A8 monoclonal antibodies using hybridoma technology. Lastly, the high binding activity of the antibody was confirmed and its sequence was identified. Conclusions: This method, including the production of antigens and antibodies, will be useful for the generation of hybridoma cell lines that produce anti-S100A8 monoclonal antibodies. Moreover, the sequence information of the antibody can be used to develop a recombinant antibody for use in various research and clinical applications. © 2023, The Author(s), under exclusive licence to Springer Nature B.V. | - |
dc.format.extent | 12 | - |
dc.publisher | Springer Science and Business Media B.V. | - |
dc.title | Generation of a novel monoclonal antibody against inflammatory biomarker S100A8 using hybridoma technology | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.1007/s10529-023-03364-0 | - |
dc.identifier.scopusid | 2-s2.0-85151074110 | - |
dc.identifier.wosid | 000956847000001 | - |
dc.identifier.bibliographicCitation | BIOTECHNOLOGY LETTERS, v.45, no.5-6, pp 589 - 600 | - |
dc.citation.title | BIOTECHNOLOGY LETTERS | - |
dc.citation.volume | 45 | - |
dc.citation.number | 5-6 | - |
dc.citation.startPage | 589 | - |
dc.citation.endPage | 600 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.subject.keywordPlus | GINGIVAL CREVICULAR FLUID | - |
dc.subject.keywordPlus | CALCIUM-BINDING PROTEINS | - |
dc.subject.keywordPlus | MRP14 | - |
dc.subject.keywordAuthor | Hybridoma technology | - |
dc.subject.keywordAuthor | Inflammation | - |
dc.subject.keywordAuthor | Monoclonal antibody | - |
dc.subject.keywordAuthor | MRP8 | - |
dc.subject.keywordAuthor | S100A8 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
94, Wausan-ro, Mapo-gu, Seoul, 04066, Korea02-320-1314
COPYRIGHT 2020 HONGIK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.